文献速递血液淋巴病理

粗针活检在淋巴瘤诊断中的表现及多学科协作优化作用

Core Needle Biopsy in Lymphoma Diagnosis: The Diagnostic Performance and the Role of the Multidisciplinary Approach in the Optimization of Results.
PubMed 文献 · Am J Surg Pathol · 2022-11-02

单中心2013至2017年476例淋巴组织增生样本分为粗针活检组218例与手术切除活检组258例,粗针活检诊断准确率为91.3%,手术切除活检为97.3%(P=0.010)。临床信息、免疫组化和流式细胞术对最终诊断有额外贡献,T细胞淋巴瘤和经典霍奇金淋巴瘤的粗针活检非诊断率较高。粗针活检由经验丰富的团队实施时安全有效,介入放射科与病理科协作是获得高特异性诊断率的关键。

要点

  • 粗针活检诊断准确率91.3%,低于手术切除活检的97.3%(P=0.010)。
  • T细胞淋巴瘤粗针活检非诊断率达30%,经典霍奇金淋巴瘤为10.6%。
  • 介入放射科与病理科协作是粗针活检获得高诊断率的关键。

核心结论

  • 粗针活检在淋巴瘤诊断中安全有效,但诊断准确率低于手术切除活检(91.3% vs 97.3%,P=0.010)。
  • 粗针活检应由经验丰富的多学科团队实施,介入放射科与病理科协作是获得高特异性诊断率的关键。

研究设计与样本

  • 单中心2013至2017年淋巴组织增生样本476例,分为粗针活检组218例和手术切除活检组258例。
  • 按世界卫生组织造血和淋巴组织肿瘤分类评估确诊百分比作为诊断准确率。

主要发现

  • 手术切除活检诊断准确率97.3%,粗针活检91.3%(P=0.010)。
  • 临床信息对最终诊断的额外贡献在粗针活检组为20.6%,手术切除活检组为7.4%(P<0.001)。
  • 免疫组化对最终诊断的额外贡献在粗针活检组为96.3%,手术切除活检组为91.5%(P=0.024)。
  • 流式细胞术对最终诊断的额外贡献在粗针活检组为12%,手术切除活检组为6.8%(P=0.165)。
  • 其他补充检测对最终诊断的额外贡献在粗针活检组为8.2%,手术切除活检组为17.3%(P=0.058)。

关键数值与推荐

  • 粗针活检非诊断率在T细胞淋巴瘤中为30%,在经典霍奇金淋巴瘤中为10.6%。
  • 术中标本 adequacy 评估、碎片数量和大小、穿刺针口径不影响诊断表现。
  • 粗针活检的主要局限在于评估形态学异质性疾病。

临床怎么用

  • 粗针活检可用于淋巴瘤诊断,但需由经验丰富的专业团队实施。
  • 介入放射科团队与病理科协作是粗针活检获得足够特异性诊断率的关键。
  • 对T细胞淋巴瘤和经典霍奇金淋巴瘤,需注意粗针活检非诊断率较高。

局限性

  • 粗针活检在形态学异质性疾病评估方面存在局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To compare the diagnostic accuracy of core needle biopsies (CNBs) and surgical excisional biopsies (SEBs), samples of lymphoid proliferation from a single institution from 2013 to 2017 (N=476) were divided into groups of CNB (N=218) and SEB (N=258). The diagnostic accuracy of these samples was evaluated as a percentage of conclusive diagnosis, according to the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues . The contribution of clinical data, the assessment of sample adequacy by a pathologist during the procedure, the number and size of fragments, the needle gauge, the ancillary tests, and the type of lymphoid proliferation were also examined. The diagnostic accuracy of SEB was 97.3% and CNB 91.3% ( P =0.010). Additional factors considered essential for establishing the final diagnosis in some cases were: clinical information (20.6% CNB, 7.4% SEB; P <0.001); immunohistochemistry (96.3% CNB, 91.5% SEB; P =0.024); flow cytometry (12% CNB, 6.8% SEB; P =0.165); and other complementary tests (8.2% CNB, 17.3% SEB; P =0.058). Factors that did not influence performance were the evaluation of sample adequacy during the procedure, the number and size of fragments, and the needle gauge. Increased percentage of nondiagnostic CNB was observed in T-cell lymphomas (30%), followed by classic Hodgkin lymphoma (10.6%). The main limitation of CNB was the evaluation of morphologically heterogenous diseases. CNB is useful and safe in lymphoma diagnosis provided it is carried out by a team of experienced professionals. Having an interventional radiology team engaged with pathology is an essential component to achieve adequate rates of specific diagnoses in CNB specimens.

来源:Am J Surg Pathol,查看原文。版权归原作者所有。

引用

  1. Gonçalves MC, de Oliveira CRGCM, Sandes AF, et al. Core Needle Biopsy in Lymphoma Diagnosis: The Diagnostic Performance and the Role of the Multidisciplinary Approach in the Optimization of Results. Am J Surg Pathol. 2022. PMID: 36395467. doi:10.1097/PAS.0000000000001991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。